

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 15 of 15 returned.**☐ 1. Document ID: US 20030021810 A1

L2: Entry 1 of 15

File: PGPB

Jan 30, 2003

PGPUB-DOCUMENT-NUMBER: 20030021810

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030021810 A1

TITLE: Chlorotoxin inhibition of cell invasion, cancer metastasis, angiogenesis and tissue remodeling

PUBLICATION-DATE: January 30, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sontheimer, Harald W.	Birmingham	AL	US	
Garner, Craig C.	Birmingham	AL	US	
Deshane, Jessy	Hoover	AL	US	

US-CL-CURRENT: 424/236.1

ABSTRACT:

The present invention provides methods of treating individuals having a pathophysiological conditions that involve the activity of matrix metalloproteinase-2/pro-MMP2 system, comprising the step of: administering to said individual a pharmaceutical composition comprising a pharmaceutically effective dose of chlorotoxin and a pharmaceutically acceptable carrier.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMOC
Draw Desc	Image										

☐ 2. Document ID: US 20020119560 A1

L2: Entry 2 of 15

File: PGPB

Aug 29, 2002

PGPUB-DOCUMENT-NUMBER: 20020119560

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020119560 A1

TITLE: Device for measuring cell invasion and method therefor

PUBLICATION-DATE: August 29, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mannuzza, Frank J.	Chelmsford	MA	US	
Flaherty, Paula	Tyngsboro	MA	US	
Ilsley, Stephen R.	Boston	MA	US	
Kramer, Martin L.	Needham	MA	US	

US-CL-CURRENT: 435/287.9

ABSTRACT:

A porous membrane is coated with a composition which includes a reconstituted and aggregated extracellular matrix derived from the Englebreth-Holm-Swarm mouse tumor, a polyol and a pH 7.8-8.2 buffer. The coated membrane is dried, affixed to an insert portion of an assembly and received in a well of a multiwell tissue culture plate. The invention includes a method to make the coated membrane.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC
Draw Desc	Image										

☐ 3. Document ID: US 20020090654 A1

L2: Entry 3 of 15

File: PGPB

Jul 11, 2002

PGPUB-DOCUMENT-NUMBER: 20020090654

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20020090654 A1

TITLE: METALLOPROTEINASE INHIBITOR

PUBLICATION-DATE: July 11, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
LANGLEY, KEITH E.	NEWBURY PARK	CA	US	
DECLERCK, YVES A.	LOS ANGELES	CA	US	
BOONE, THOMAS C.	NEWBURY PARK	CA	US	

US-CL-CURRENT: 435/7.2; 424/130.1, 435/326, 536/7.2

ABSTRACT:

A novel metalloproteinase inhibitor, analogs thereof, polynucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders caused by excessive amounts of metalloproteinase are also disclosed.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC
Draw Desc	Image										

☐ 4. Document ID: US 20020072115 A1

L2: Entry 4 of 15

File: PGPB

Jun 13, 2002

PGPUB-DOCUMENT-NUMBER: 20020072115
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020072115 A1

TITLE: Pancreatic islet cell growth factors

PUBLICATION-DATE: June 13, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Harrison, Leonard C.	Victoria		AU	
Jiang, Fang-Xu	Victoria		AU	
Stanley, Edouard Guy	Victoria		AU	
Gonez, Leonel Jorge	Victoria		AU	

US-CL-CURRENT: 435/325; 435/366, 435/384

ABSTRACT:

The present invention relates generally to growth factors and more particularly to growth factors which are capable of stimulating or otherwise facilitating formation of insulin-secreting cells. The identification of these growth factors permits the development of protocols to culture cells in vitro for transplantation into mammalian and in particular human subjects with insulin-dependent type 1 diabetes or related conditions. It is further contemplated that the endogenous expression of growth factors required for the development of insulin-producing cells may be manipulated in vivo, by the appropriate administration of agents including genetic agents capable of regulating the expression of growth factors in pancreatic duct epithelial cells. The growth factors may also be administered to subjects with type 1 diabetes to stimulate the proliferation and differentiation of pancreatic cells into insulin-secreting cells. The present invention also provides modulators of growth factor-mediated pancreatic cell differentiation. Such modulators are useful in the treatment inter alia of .beta. cell tumors and/or pancreatic cancer.

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 5. Document ID: US 6160166 A

L2: Entry 5 of 15

File: USPT

Dec 12, 2000

US-PAT-NO: 6160166
DOCUMENT-IDENTIFIER: US 6160166 A

TITLE: Phosphonated agents and their antiangiogenic and antitumorigenic use

DATE-ISSUED: December 12, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Collins; Delwood C.	Lexington	KY		
Gagliardi; Antonio R.	Lexington	KY		
Nickel; Peter	Bonn			DE

US-CL-CURRENT: 562/16; 562/11, 562/20, 562/23, 562/24

ABSTRACT:

Phosphonic acid agents are synthesized and characterized which are potent inhibitors of angiogenesis, tumorigenesis and metalloproteinase activity. Their method of use for the inhibition of angiogenesis and metalloproteinase and the treatment of tumors is also shown.

10 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

K00C

☐ 6. Document ID: US 6096730 A

L2: Entry 6 of 15

File: USPT

Aug 1, 2000

US-PAT-NO: 6096730

DOCUMENT-IDENTIFIER: US 6096730 A

TITLE: Phosphonated agents and their antiangiogenic and antitumorigenic use

DATE-ISSUED: August 1, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Collins; Delwood C.	Lexington	KY		
Gagliardi; Antonio R.	Lexington	KY		
Nickel; Peter	Bonn			DE

US-CL-CURRENT: 514/107; 514/114, 514/115, 514/116, 562/12, 562/13, 562/15, 562/23

ABSTRACT:

Phosphonic acid agents are synthesized and characterized which are potent inhibitors of angiogenesis, tumorigenesis and metalloproteinase activity. Their method of use for the inhibition of angiogenesis and metalloproteinase and the treatment of tumors is also shown.

8 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

K00C

☐ 7. Document ID: US 6087157 A

L2: Entry 7 of 15

File: USPT

Jul 11, 2000

US-PAT-NO: 6087157

DOCUMENT-IDENTIFIER: US 6087157 A

TITLE: Device and method for analyzing tumor cell invasion of an extracellular matrix

DATE-ISSUED: July 11, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Badylak; Stephen F.	West Lafayette	IN		
Boder; George	Martinsville	IN		
Voytik-Harbin; Sherry L.	Lafayette	IN		
Demeter; Robert J.	Mooreville	IN		
Critser; John K.	Carmel	IN		
Liu; Chi	Indianapolis	IN		

US-CL-CURRENT: 435/289.1; 435/284.1, 435/287.1, 435/287.9, 435/288.4, 435/297.1,
435/299.1, 435/304.1, 435/391, 435/4, 435/7.21, 435/7.23

ABSTRACT:

A device for analyzing the in-vitro growth properties of cells is disclosed. The device comprises an upper and lower chamber separated by a growth substrate interface comprising submucosa, preferably tunical submucosa, from a warm-blooded vertebrae. Methods for culturing eukaryotic cells and studying their growth characteristics, including the invasive growth characteristics of tumor cells, on the submucosal matrix are described.

13 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KIMC
Draw Desc	Image									

☐ 8. Document ID: US 5994292 A

L2: Entry 8 of 15

File: USPT

Nov 30, 1999

US-PAT-NO: 5994292

DOCUMENT-IDENTIFIER: US 5994292 A

TITLE: Interferon-inducible protein 10 is a potent inhibitor of angiogenesis

DATE-ISSUED: November 30, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Tosato; Giovanna	Bethesda	MD		
Angiolillo; Anne L.	Washington	DC		
Sgadari; Cecilia	Bethesda	MD		

US-CL-CURRENT: 514/2; 514/12, 514/21, 514/4, 530/300, 530/324, 530/325, 530/326,
530/327, 530/328

ABSTRACT:

The present invention is interferon-inducible protein 10 and fragments and analogs of interferon-inducible protein 10 as inhibitors of angiogenesis. The present invention is also the use of interferon-inducible protein 10 (IP-10) as well as fragments and analogs of IP-10 as potent inhibitors of angiogenesis. IP-10 profoundly inhibited basic fibroblast growth factor (bFGF)-induced neovascularization in immunocompromised

mammals. In addition, IP-10, is useful in a dose-dependent fashion in suppressing endothelial cell differentiation into tubular capillary structures.

35 Claims, 13 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 10

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 9. Document ID: US 5872106 A

L2: Entry 9 of 15

File: USPT

Feb 16, 1999

US-PAT-NO: 5872106
DOCUMENT-IDENTIFIER: US 5872106 A

TITLE: Antimessenger oligonucleotide against urokinase receptor

DATE-ISSUED: February 16, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Capaccioli; Sergio	Florence			IT
Del Rosso; Mario	Florence			IT
Fibbi; Gabriella	Florence			IT
Quattroni; Alessandro	Florence			IT

US-CL-CURRENT: 514/44; 435/366, 435/375, 435/6, 435/91.1, 536/23.1, 536/24.31, 536/24.5

ABSTRACT:

Antisense oligonucleotides optionally stabilized with phosphorotioate residues or analogues, or modified in the whole sugar-phosphate backbone--complementary to the human urokinase receptor messenger RNA--are able to prevent invasiveness of neoplastic cells by inhibiting the overexpression of the receptor itself, directly responsible of the invasive phenotype. Said oligomers are useful as medicaments for the treatment of primary and secondary neoplasias as well as of other pathologies wherein the urokinase receptor gene overexpression is a pathogenic event.

4 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KMC
Draw Desc	Image									

☐ 10. Document ID: US 5811281 A

L2: Entry 10 of 15

File: USPT

Sep 22, 1998

US-PAT-NO: 5811281
DOCUMENT-IDENTIFIER: US 5811281 A

TITLE: Immortalized intestinal epithelial cell lines

DATE-ISSUED: September 22, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Quaroni; Andrea	Ithaca	NY		
Paul; Eileen C. A.	Ithaca	NY		

US-CL-CURRENT: 435/353; 435/320.1, 435/467

ABSTRACT:

Novel intestinal epithelial cell lines having stably incorporated heterologous DNA having a temperature-sensitive mutant oncogene are described, wherein the cell line proliferates at permissive temperatures in a conditionally immortalizing phenotype; and ceases to proliferate at nonpermissive temperatures thereby effecting cessation of cell proliferation and a differentiated intestinal epithelial cell phenotype including expression of certain brush border enzymes, and keratin markers.

4 Claims, 7 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWIC
Draw Desc	Image									

☐ 11. Document ID: US 5714465 A

L2: Entry 11 of 15

File: USPT

Feb 3, 1998

US-PAT-NO: 5714465

DOCUMENT-IDENTIFIER: US 5714465 A

TITLE: Method of inhibiting tumor cell dissemination with a metalloproteinase inhibitor

DATE-ISSUED: February 3, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Langley; Keith E.	Newbury Park	CA		
DeClerck; Yves A.	Los Angeles	CA		
Boone; Thomas C.	Newbury Park	CA		

US-CL-CURRENT: 514/12; 514/2, 530/350

ABSTRACT:

A novel metalloproteinase inhibitor, analogs thereof, polynucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders caused by excessive amounts of metalloproteinase are also disclosed. In particular, a method for inhibiting tumor cell dissemination in a mammal comprising administering an effective amount of such metalloproteinase inhibitors is described.

4 Claims, 55 Drawing figures

Exemplary Claim Number: 1
Number of Drawing Sheets: 32

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

K00C

☐ 12. Document ID: US 5580960 A

L2: Entry 12 of 15

File: USPT

Dec 3, 1996

US-PAT-NO: 5580960

DOCUMENT-IDENTIFIER: US 5580960 A

TITLE: KS-laminin and methods of use

DATE-ISSUED: December 3, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Burgeson; Robert E.	Charlestown	MA		
Champlaud; Marie-France	Boston	MA		

US-CL-CURRENT: 530/395; 530/343, 530/350, 530/842, 530/851

ABSTRACT:

KS-laminin and a KS-laminin-kalinin adduct are disclosed. The molecules of the invention are useful for promoting the adhesion of keratinocytes to a substrate.

1 Claims, 0 Drawing figures

Exemplary Claim Number: 1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

K00C

☐ 13. Document ID: US 4945086 A

L2: Entry 13 of 15

File: USPT

Jul 31, 1990

US-PAT-NO: 4945086

DOCUMENT-IDENTIFIER: US 4945086 A

TITLE: Smooth muscle cell growth inhibitor

DATE-ISSUED: July 31, 1990

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Benitz; William E.	Palo Alto	CA		
Bernfield; Merton	Palo Alto	CA		

US-CL-CURRENT: 514/56; 536/21

ABSTRACT:

An epithelium-derived inhibitor of the growth of smooth muscle cells is disclosed along with methods for purifying this substance. As initially isolated, the inhibitor comprises a heparan sulfate proteoglycan having a buoyant density of less than 1.4 g/ml which releases a glycosaminoglycan chain having a molecular weight of about 55,000 to 75,000 on protease cleavage. Growth inhibiting activity is found in the glycosaminoglycan chain and in glycosaminoglycan fragments derived therefrom. Use of a dialyzable detergent in purification steps greatly aids in the handling and purification of the inhibitor. The inhibitor can be used in a variety of techniques for inhibiting the growth of smooth muscle cells, both in vivo and in vitro.

29 Claims, 0 Drawing figures
Exemplary Claim Number: 1,15

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWMC
Draw Desc	Image									

☐ 14. Document ID: EP 1195432 A2

L2: Entry 14 of 15

File: EPAB

Apr 10, 2002

PUB-NO: EP001195432A2

DOCUMENT-IDENTIFIER: EP 1195432 A2

TITLE: Porous membrane comprising an extracellular membrane and a polyol


PUBN-DATE: April 10, 2002

INVENTOR-INFORMATION:

NAME	COUNTRY
MANNUZZA, FRANK J	US
FLAHERTY, PAULA	US
ILLSLEY, STEPHEN R	US
KRAMER, MARTIN L	US

INT-CL (IPC): C12 N 5/00

ABSTRACT:

CHG DATE=20020503 STATUS=O> A porous membrane is coated with a composition which includes a reconstituted and aggregated extracellular matrix derived from the Englebreth-Holm-Swarm mouse tumor, a polyol and a pH 7.8-8.2 buffer. The coated membrane is dried, affixed to an insert portion of an assembly and received in a well of a multiwell tissue culture plate. The invention includes a method to make the coated membrane. 

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	KWMC
Draw Desc	Image									

☐ 15. Document ID: JP 2002320472 A EP 1195432 A2 AU 200176107 A CA 2357846 A1 US 20020119560 A1

L2: Entry 15 of 15

File: DWPI

Nov 5, 2002

DERWENT-ACC-NO: 2002-445985
DERWENT-WEEK: 200304
COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Coated membrane for assessing invasiveness of cells, useful e.g. for studying toxicity, comprises porous membrane coated with reconstituted extracellular matrix

INVENTOR: FLAHERTY, P; ILSLEY, S R ; KRAMER, M L ; MANNUZZA, F J ; ILLSLEY, S R

PRIORITY-DATA: 2001US-0942349 (August 29, 2001), 2000US-235712P (September 27, 2000)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
JP 2002320472 A	November 5, 2002		021	C12M003/00
EP 1195432 A2	April 10, 2002	E	008	C12N005/00
AU 200176107 A	March 28, 2002		000	C12M003/04
CA 2357846 A1	March 27, 2002	E	000	C12Q001/02
US 20020119560 A1	August 29, 2002		000	C12M001/34

INT-CL (IPC): C12 M 1/34; C12 M 3/00; C12 M 3/04; C12 N 5/00; C12 Q 1/02

ABSTRACTED-PUB-NO: EP 1195432A

BASIC-ABSTRACT:

NOVELTY - A coated membrane (A) for assessing the invasive capacity of a cell comprising a porous membrane having, on its surface, a composition (B) consisting of reconstituted and aggregated extracellular matrix (ECM) from the Englebreth-Holm-Swarm mouse tumor, pH 7.8-8.2 buffer and a polyol (I), is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) an assembly for assessing invasive capacity of cells that includes (A); and
- (2) method for preparing (A).

USE - The device is used to measure invasion of cells through aggregated ECM, e.g. for studying bioavailability, toxicity, or migration, attachment, growth and invasiveness of cells.

ADVANTAGE - (B) provides a uniform and clear coating, and thus even invasion over its entire surface, and is readily digested by invasive cells, but resists passage of non-invasive cells, allowing easy and accurate differentiation between these cell types. (B) mimics the natural basement membrane and provides the proper environment for growth, attachment and penetration of cells. The coating is stable for at least 4 weeks at 4 deg. C (contrast 1 week for similar coatings prepared using pH 7.4 phosphate buffer) and addition of (I) prevents precipitation of salt (responsible for non-uniformities).

ABSTRACTED-PUB-NO:

US20020119560A EQUIVALENT-ABSTRACTS:

NOVELTY - A coated membrane (A) for assessing the invasive capacity of a cell comprising a porous membrane having, on its surface, a composition (B) consisting of reconstituted and aggregated extracellular matrix (ECM) from the Englebreth-Holm-Swarm mouse tumor, pH 7.8-8.2 buffer and a polyol (I), is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) an assembly for assessing invasive capacity of cells that includes (A); and
- (2) method for preparing (A).

USE - The device is used to measure invasion of cells through aggregated ECM, e.g. for studying bioavailability, toxicity, or migration, attachment, growth and invasiveness of cells.

ADVANTAGE - (B) provides a uniform and clear coating, and thus even invasion over its entire surface, and is readily digested by invasive cells, but resists passage of non-invasive cells, allowing easy and accurate differentiation between these cell types. (B) mimics the natural basement membrane and provides the proper environment for growth, attachment and penetration of cells. The coating is stable for at least 4 weeks at 4 deg. C (contrast 1 week for similar coatings prepared using pH 7.4 phosphate buffer) and addition of (I) prevents precipitation of salt (responsible for non-uniformities).

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
Draw Desc	Image								

KVMC

[Generate Collection](#)[Print](#)

Term	Documents
POLYOL.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	81405
POLYOLS.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	51470
SUCROSE.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	87471
SUCROSES.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	88
SUGAR.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	151398
SUGARS.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	50236
GLYCOL.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	360607
GLYCOLS.DWPI,TDBD,EPAB,JPAB,USPT,PGPB.	86405
(1 AND (SUCROSE OR SUGAR OR POLYOL OR GLYCOL)).USPT,PGPB,JPAB,EPAB,DWPI,TDBD.	15
(L1 AND (POLYOL OR SUCROSE OR SUGAR OR GLYCOL)).USPT,PGPB,JPAB,EPAB,DWPI,TDBD.	15

Display Format: [Change Format](#)[Previous Page](#)[Next Page](#)